Like the humble hero in the better know fairytale Chemelot is quiet and unsung yet it is a proven open innovation platform with a track record boasting commercial manufacturing experience for 2 of the 3 approved cell therapies in Europe.
With state of the art clean rooms and lab space to available to rent and potential VC funding on offer Limburg’s Chemelot is hoping to be an attractive option for new companies entering the regenerative medicine space but also for existing companies planning a European foothold. With facilities, infrastructure, expertise and funding at their side can they capture and share this knowledge which is so precious to both private companies and other stakeholders of the emerging cell therapy industry?
Kurt Gielen their business development manager welcomes dialogue with the Uk’s Cell Therapy Catapult and Belgium’s Regenerative Medicine Platform as well as academic institutions around Europe so maybe accelerating development is on the cards and will Chemelot invite more players to their round table?
Vishal Sharma for Total BioPharma at the World Stem Cells and Regenerative Medicine Congress.